Therapeutic cancer vaccines offer hope for patients for whom traditional treatments have failed, but various obstacles may impede the launch of these new agents.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models
Journal of Translational Medicine Open Access 10 November 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Edwards, B.K. et al. Annual report to the nation on the status of cancer, 1973–1999, featuring implications of age and aging on US cancer burden. Cancer 94, 2766–2792 (2002).
Armstrong, A.C. et al. Science, medicine, and the future: Cellular immunotherapy for cancer. BMJ 323, 1289–1293 (2001).
Dalgleish, A.D. Cancer vaccines. Br. J. Cancer 82, 1619–1624 (2000).
Armstrong, A.C. & Hawkins, R.E. Vaccines in oncology: background and clinical potential. Br. J. Radiol. 74, 991–1002 (2001).
Durrant, L.G. Cancer vaccines. Anticancer Drugs 8, 727–733 (1997).
Pardoll, D.M. Cancer vaccines. Nat. Med. 4, 525–531 (1998).
Timmerman, J.M. & Levy, R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med. 50, 507–529 (1999).
Reichert, J.M. Therapeutic monoclonal antibodies: trends in development and approval in the US. Curr. Opin. Mol. Ther. 4, 110–118 (2002).
Kaitin, K.I. & Healy, E.M. The new drug approvals of 1996, 1997, and 1998: drug development trends in the user fee era. Drug Inf. J. 34, 1–14 (2000).
Reichert, J.M. et al. The effects of the Prescription Drug User Fee Act and the Food and Drug Administration Modernization Act on the development and approval of therapeutic medicines. Drug Inf. J. 35, 85–94 (2001).
Chung, K.-T. & Biggers, C.J. Albert Léon Charles Calmette (1863–1933) and the antituberculous BCG vaccination. Perspect. Biol. Med. 44, 379–389 (2001).
Acknowledgements
Funding for this work was provided in part by a grant from the Drug Information Association (Fort Washington, PA).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Reichert, J., Paquette, C. Therapeutic cancer vaccines on trial. Nat Biotechnol 20, 659–663 (2002). https://doi.org/10.1038/nbt0702-659
Issue Date:
DOI: https://doi.org/10.1038/nbt0702-659
This article is cited by
-
Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models
Journal of Translational Medicine (2010)
-
Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy
Breast Cancer Research and Treatment (2005)